Refine
Document Type
- Article (2)
- Doctoral Thesis (1)
Language
- English (3)
Has Fulltext
- yes (3)
Is part of the Bibliography
- no (3)
Keywords
- ketamine (3) (remove)
Institute
Introduction: Ketamine (KET) is widely used as anaesthetic drug. Beside its pronounced an-aesthetic effects as caused by antagonism of NMDA receptors, ketamine also causes potent analgesia. Moreover, There are ample new evidences, firstly, that 2R,6R/2S,6S-enantiomers of hydroxynorketamine (HNK), exert neuro-modulating effects by AMPA-receptor activation and, secondly, that the plasma levels of norketamine (n-KET) after oral dosing are higher than after intravenous administration. From the physicochemical point of view ketamine is expected to be a substrate of drug transporters. Thus, it was the aim of this study to separate and quantify KET and its metabolites in human serum, urine and feces; investigate the role of transporter proteins in the intestinal absorption, distribution and elimination of ketamine; and evaluate pharmacokinetics and metabolism of a newly developed prolonged-release keta-mine dosage form to confirm its suitability for chronic treatment of CNS-diseases (e.g. de-pression) according to the new “ketamine metabolite paradigm”. Materials and methods: Quantification of ketamine was done by a LC-MS/MS-based quantifi-cation method on the QTRAP4000 instrument. Samples were extracted by methyl tert-butyl ether after addition of sodium carbonate to liberate the free base; Single transfected MDCKII cells overexpressing OCT1, OCT2, OCT3, and MATE1 or MATE2K, and HEK293 cells over-expressing OATP2B1 were used to study the cellular uptake of ketamine. Inside-out lipovesi-cles were used to determine the affinity of ketamine to the efflux transporter P-glycoprotein (P-gp). Uptake into cells or vesicles was determined by liquid scintillation counting. Func-tionality of all in vitro systems was assured by using in each case appropriate probe sub-strates; The dose-escalation study was performed in five consecutive periods (7 days wash-out) in 15 healthy subjects (5 females and 10 males. 20-35 years, BMI 19.4-27.6 kg/m2). Results: We introduce for the first time the separation and quantification of the active me-tabolites 2R,6R/2S,6S-HNK; Ketamine was shown to be taken up significantly in a time- and concentration-dependent manner by OCT1-3. The affinity to OCT transporters at pH=6.5 was several fold higher than that at pH=7.4. ), ketamine showed a significant but low affinity to P-gp. In contrast to this, we could not detect any transport of ketamine by MATE1 / 2K or OACPT2B1; and PR-KET was safe and well tolerated with higher metabolites productivity, different pharmacokinetic properties and longer T1/2 when compared to IV-KET or IR-KET. Conclusion: the uptake transporters OCT1 & 3 and the efflux transporter P-gp may play a role in the intestinal absorption of the drug. On the other side, P-gp, MATE1 / 2K and OCT are not expected to contribute significantly to tissue (brain) distribution or renal excretion of ketamine; Moreover, the prolonged-release ketamine undergoes dose-dependent “first-pass” metabolism which generates substantially increased plasma exposure of downstream me-tabolites with potential neuro-modulating effects compared to ketamine after intravenous administration.
Abstract
Modeling of metabolite kinetics after oral administration of ketamine is of special interest because of the higher concentrations of active metabolites because of the hepatic first‐pass effect. This holds especially in view of the potential analgesic and antidepressant effects of 2R,6R‐ and 2S,6S‐hydroxynorketamine at low doses of ketamine. Therefore, a 9‐compartment model was developed to analyze the pharmacokinetics of ketamine enantiomers and their metabolites after racemic ketamine administered intravenously (5 mg) and as 4 doses (10, 20, 40, and 80 mg) of a prolonged‐release formulation (PR‐ketamine). Using a population approach, the serum concentration‐time data of the enantiomers of ketamine, norketamine, dehydronorketamine, and 2,6‐hydroxynorketamine obtained in 15 healthy volunteers could be adequately fitted. The estimated model parameters were used to simulate serum concentration‐time profiles; after multiple dosing of PR‐ketamine (2 daily doses of 20 mg), the steady‐state concentrations of R‐ and S‐ketamine were 1.4 and 1.3 ng/mL, respectively. The steady‐state concentration of 2R,6R‐hydroxynorketamine exceeded those of R‐norketamine (4‐fold), R‐dehydonorketamine (8‐fold), and R‐ketamine (46‐fold), whereas that of 2S,6S‐hydroxynorketamine exceeded that of S‐ketamine by 14‐fold. The model may be useful for identifying dosing regimens aiming at optimal plasma concentrations of 2,6‐hydroxynorketamines.